Loading...
XNASACET
Market cap75mUSD
Jan 17, Last price  
0.92USD
1D
0.05%
1Q
-36.54%
IPO
-94.33%
Name

Adicet Bio Inc

Chart & Performance

D1W1MN
XNAS:ACET chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.63%
Rev. gr., 5y
-46.28%
Revenues
0k
-100.00%
359,591,000322,646,000346,631,000412,428,000444,388,000499,690,000499,690,000510,179,000546,951,000558,524,0008,181,000995,00017,903,0009,730,00024,990,0000
Net income
-143m
L+112.83%
13,473,0008,629,0006,581,0008,968,00016,981,00022,328,00022,328,00029,000,000-1,000-33,778,000-9,299,000-28,138,000-36,678,000-61,999,000-67,029,000-142,658,000
CFO
-94m
L+109.35%
15,418,00022,511,000-15,499,00014,038,00013,269,00023,731,00025,476,00025,056,0008,343,000-11,553,000-18,180,000-27,882,000-41,552,000-51,052,000-44,765,000-93,717,000
Dividend
Sep 21, 20180.0014 USD/sh
Earnings
Mar 17, 2025

Profile

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
URL
https://www.adicetbio.com/
IPO date
Jan 26, 2018
Employees
132
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑062016‑062015‑06
Income
Revenues
24,990
156.83%
Cost of revenue
138,674
102,550
Unusual Expense (Income)
NOPBT
(138,674)
(77,560)
NOPBT Margin
Operating Taxes
(2,761)
Tax Rate
NOPAT
(138,674)
(74,799)
Net income
(142,658)
112.83%
(67,029)
8.11%
Dividends
Dividend yield
Proceeds from repurchase of equity
236
40,126
BB yield
-0.29%
-10.93%
Debt
Debt current
6,442
2,492
Long-term debt
38,627
39,554
Deferred revenue
Other long-term liabilities
130
114
Net debt
(114,642)
(215,610)
Cash flow
Cash from operating activities
(93,717)
(44,765)
CAPEX
(4,464)
(16,782)
Cash from investing activities
(4,464)
(16,782)
Cash from financing activities
236
41,509
FCF
(133,896)
(88,777)
Balance
Cash
159,711
257,656
Long term investments
Excess cash
159,711
256,406
Stockholders' equity
(380,768)
(238,110)
Invested Capital
575,218
21,133
ROIC
ROCE
EV
Common stock shares outstanding
43,042
41,080
Price
1.89
-78.86%
8.94
-48.89%
Market cap
81,350
-77.85%
367,258
-32.16%
EV
(33,292)
151,648
EBITDA
(132,576)
(74,985)
EV/EBITDA
0.25
Interest
80
Interest/NOPBT